Moderna Inc. briefly soared above a $100 billion valuation on Wednesday as vaccinations against the Covid-19 virus continue to ramp up across the globe. Shares of the drug developer rose as much as 6.3% to a fresh record, propelling its market value to that milestone before closing 4.9% higher at $246.66. Moderna has surged more than 220% over the past 12 months as drugmakers raced to develop a vaccine against the coronavirus.